J
Julian B. S. Leathart
Researcher at Newcastle University
Publications - 48
Citations - 4774
Julian B. S. Leathart is an academic researcher from Newcastle University. The author has contributed to research in topics: Fatty liver & Genotype. The author has an hindex of 30, co-authored 48 publications receiving 4419 citations. Previous affiliations of Julian B. S. Leathart include University of Newcastle & Bosch.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Munir Pirmohamed,Girvan Burnside,Niclas Eriksson,Andrea L. Jorgensen,Cheng Hock Toh,Toby Nicholson,Patrick Kesteven,Christina Christersson,Bengt Wahlström,Christina Stafberg,J. Eunice Zhang,Julian B. S. Leathart,Hugo Kohnke,Anke H. Maitland-van der Zee,Paula R Williamson,Ann K. Daly,Peter Avery,Farhad Kamali,Mia Wadelius,Abstr Act +19 more
TL;DR: Pharmacogenetic-based dosing was associated with a higher percentage of time in the therapeutic INR range than was standard dosing during the initiation of warfarin therapy.
Journal ArticleDOI
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Yang-Lin Liu,Helen L. Reeves,Alastair D. Burt,Dina Tiniakos,Stuart McPherson,Julian B. S. Leathart,Michael Allison,Graeme J.M. Alexander,Anne Christine Piguet,Rodolphe Anty,Peter T. Donaldson,Guruprasad P. Aithal,Sven Francque,Luc Van Gaal,Karine Clément,Vlad Ratziu,Jean-François Dufour,Christopher P. Day,Ann K. Daly,Quentin M. Anstee +19 more
TL;DR: It is confirmed that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN.
Journal ArticleDOI
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
Y-L Liu,G.L. Patman,Julian B. S. Leathart,Anne Christine Piguet,Alastair D. Burt,Jean-François Dufour,C.P. Day,Ann K. Daly,Helen L. Reeves,Quentin M. Anstee +9 more
TL;DR: It is suggested that PNPLA3 genotyping has the potential to contribute to multi-factorial patient-risk stratification, identifying those to whom HCC surveillance may be targeted.
Journal ArticleDOI
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Mikko Niemi,Mikko Niemi,Mikko Niemi,Janne T. Backman,Janne T. Backman,Janne T. Backman,Lauri I. Kajosaari,Lauri I. Kajosaari,Lauri I. Kajosaari,Julian B. S. Leathart,Julian B. S. Leathart,Julian B. S. Leathart,Mikko Neuvonen,Mikko Neuvonen,Mikko Neuvonen,Ann K. Daly,Ann K. Daly,Ann K. Daly,Michel Eichelbaum,Michel Eichelbaum,Michel Eichelbaum,Kari T. Kivistö,Kari T. Kivistö,Kari T. Kivistö,Pertti J. Neuvonen,Pertti J. Neuvonen,Pertti J. Neuvonen +26 more
TL;DR: The aim was to investigate possible associations between the pharmacokinetics of repaglinide and single nucleotide polymorphisms (SNPs) in the genes encoding for the drug transporters organic anion transporting polypeptide 1B1 and P‐glycoprotein and the drug‐metabolizing enzymes cytochrome P450 (CYP) 2C8 and CYP3A5.
Journal ArticleDOI
Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes
Ann K. Daly,Guruprasad P. Aithal,Julian B. S. Leathart,Richard A. Swainsbury,Tarana Singh Dang,Christopher P. Day +5 more
TL;DR: Allelic variants of UGT2B7, CYP2C8, and ABCC2, which may predispose to the formation and accumulation of reactive diclofenac metabolites are associated withdicl ofenac hepatotoxicity.